HomeBUSINESS
BUSINESS

FGF23 Antibody Burosumab Earns FDA Priority Status: Kyowa Kirin/Ultragenyx
(Oct.12.2017)

Kyowa Hakko Kirin and its US partner Ultragenyx Pharmaceutical said on October 10 that the US FDA has accepted a biologics license application for their anti-FGF23 monoclonal IgG1 antibody burosumab, and granted a priority review status for the drug ...
(LOG IN FOR FULL STORY)

News Calendar